Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Trevi Therapeutics, Inc. (TRVI) had Consolidated Net Income/Loss of $-10.34M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-10.34M |
|
-- |
|
-- |
|
$11.47M |
|
$-11.47M |
|
$1.13M |
|
$-10.35M |
|
$-10.35M |
|
$-10.34M |
|
$-10.34M |
|
|
Consolidated Net Income/Loss |
$-10.34M |
$-10.34M |
|
$-11.47M |
|
$-11.43M |
|
117.61M |
|
117.61M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$105.62M |
|
$0.28M |
|
$1.38M |
|
$107.00M |
|
$6.87M |
|
-- |
|
$0.68M |
|
$7.55M |
|
$99.46M |
|
$99.46M |
|
$99.46M |
|
99.89M |
|
| Cash Flow Statement Financials | |
$-13.48M |
|
$-9.95M |
|
$8.71M |
|
$34.10M |
|
$19.37M |
|
$-14.72M |
|
$1.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.40% |
|
-10.40% |
|
-9.66% |
|
-10.40% |
|
$1.00 |
|
$-0.11 |
|
$-0.11 |
|